Longevity Science Is Moving From the Lab to the Clinic

From GLP-1 medicines to cellular reprogramming, credible research is making healthy aging one of the most promising scientific themes of the decade.

For most of history, aging was treated as a fixed process. A growing body of peer-reviewed research now suggests that parts of it can be measured, slowed and in some laboratory settings even partly reversed. The science is moving steadily from the bench toward the clinic.

The demographic backdrop gives the work real weight. The U.S. Census Bureau estimated about 101,000 Americans aged 100 or older in 2024 and projects that number will reach roughly 422,000 by 2054, as reported by Pew Research Center. Helping people stay healthy through those added years is one of the great scientific opportunities of the century.

Metabolic Medicine Opens a New Chapter

The most visible progress so far comes from GLP-1 medicines, first developed for diabetes and weight management. Their benefits are proving broader than many researchers expected, and large trials are documenting effects across several organ systems.

The landmark example is SELECT, published in the New England Journal of Medicine in 2023. The trial followed 17,604 adults with overweight or obesity and established cardiovascular disease for a mean of 40 months. Participants taking semaglutide experienced about 20% fewer major adverse cardiovascular events, such as heart attack and stroke, than those on placebo.

Follow-on studies have extended the picture:

• Kidney health: In March 2024, Novo Nordisk reported a 24% reduction in kidney disease-related events in a Phase 3 trial of semaglutide.
• Sleep apnea: In April 2024, Eli Lilly reported that tirzepatide reduced sleep apnea severity by up to 63% in adults with obesity in its SURMOUNT-OSA program.
• Liver health: In August 2025, semaglutide became the first GLP-1 medicine approved in the U.S. to treat MASH, a serious form of fatty liver disease, in adults with moderate to advanced liver fibrosis.

Together, these findings point to a powerful idea: treating a shared root cause, such as metabolic dysfunction, can improve outcomes in several age-related conditions at once. That is the central promise of longevity medicine.

The scale of these studies also matters. Trials with tens of thousands of participants and multiyear follow-up produce the kind of evidence that physicians and health systems can act on with confidence. Few areas of medicine have generated so much high-quality data so quickly.

Cellular Reprogramming: Resetting the Cellular Clock

A second frontier goes deeper, to the instructions inside each cell. In 2012, Shinya Yamanaka shared the Nobel Prize for discovering four proteins, now called the Yamanaka factors, that can return a mature cell to an embryonic-like state.

Researchers have since explored partial reprogramming, which applies these factors briefly. The goal is to restore youthful function without erasing a cell's identity. The approach appears to work by resetting epigenetic marks, the chemical tags that switch genes on and off and tend to drift with age.

Early animal work was striking. In a 2016 study led by Juan Carlos Izpisua Belmonte at the Salk Institute, brief activation of the factors extended the life expectancy of mice with a premature aging condition and restored youthful function in several organs, as Scientific American reported.

Serious capital followed the science. In January 2022, Altos Labs launched with $3 billion to pursue cellular rejuvenation. The company is led by Hal Barron, formerly chief scientific officer at GSK, with institutes in the San Francisco Bay Area, San Diego and Cambridge, U.K. Shinya Yamanaka joined as a senior scientific advisor, and Izpisua Belmonte leads the San Diego institute.

The bench is deep. Cell biologist Peter Walter leads the Bay Area institute, Wolf Reik heads the Cambridge institute and Thore Graepel leads computational science, AI and machine learning. Pairing leading biology with advanced computing reflects how modern discovery increasingly works.

The First Steps Into Human Studies

Reprogramming reached an important milestone in January 2026. Life Biosciences, a Boston biotech, announced that its therapy ER-100 would enter the first human study of partial epigenetic reprogramming.

The program targets two eye conditions that damage the optic nerve: glaucoma and non-arteritic anterior ischemic optic neuropathy. It uses three of the four Yamanaka factors, delivered locally to the eye with an on-off switch so the factors act only for a controlled period. The Phase 1 study is focused on safety and tolerability.

The eye is a thoughtful starting point. It is a contained organ, vision is measurable with precision and success would provide valuable evidence for broader applications over time.

The study also reflects a careful, stepwise culture in the field. Researchers are starting where benefits can be measured clearly and where treatment can be tightly controlled. That disciplined approach builds the trust that any new class of medicine needs to reach patients at scale.

Public Research Builds the Foundation

Private companies receive the headlines, yet publicly funded science supplies much of the groundwork. A strong example is the Interventions Testing Program, funded by the National Institute on Aging, part of the National Institutes of Health.

The program tests compounds for their effect on lifespan in genetically diverse mice at three sites: the University of Michigan, the Jackson Laboratory in Maine and UT Health Science Center at San Antonio. Running the same study at three locations makes the results more reliable. Using genetically diverse mice, rather than a single inbred strain, also makes the findings more relevant to a varied human population.

Its best-known finding involves rapamycin, which extended lifespan in both male and female mice, including maximum lifespan. Notably, the benefit appeared even when treatment began at 20 months of age, which is late in a mouse's life. That result encouraged researchers to see aging as something that may respond to intervention well into later life.

Where Momentum Is Building

Longevity is becoming a broad field rather than a single bet. Several areas are drawing talent and research attention:

• Metabolic therapeutics: New indications for GLP-1 and related medicines continue to emerge from large trials.
• Cellular rejuvenation: Partial reprogramming is moving from animal models toward carefully designed human studies.
• Biomarkers and aging clocks: Better measures of biological age help researchers judge whether an intervention is working.
• AI-assisted discovery: Machine learning helps scientists sort through vast biological datasets to find promising targets faster.
• Healthy aging services: Prevention, fitness and nutrition programs designed for longer lives are growing alongside the science.

Each area reinforces the others. Better biomarkers speed up trials, faster trials attract more capital and more capital funds the next round of discovery.

Reading the Signals Ahead

Longevity science is entering a productive phase. Large trials are confirming benefits of metabolic medicines, reprogramming has reached its first human study and public research programs continue to supply rigorous evidence. The field is building on solid ground.

A practical takeaway: follow the evidence, not the excitement. Track peer-reviewed results, note which programs move from animal studies into human trials and watch where leading scientists choose to work. Those signals tend to reveal where durable progress is forming long before it becomes common knowledge.

Most of all, keep the long view. Breakthroughs in medicine usually arrive through many careful steps, and the steady accumulation of evidence now underway is exactly what lasting progress looks like.

For general information only; not investment advice.

More insights from Jason Kumpf Capital